VIA
TEVA icon

Victrix Investment Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Victrix Investment Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$266K Buy
7,850
+681
+9% +$22.7K 0.11% 68
2026
Q1 		$216K Buy
+7,169
New +$231K 0.08% 102

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $14.9B AUM 46.8% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.63B AUM 45.28% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
KHLMVGHM
Kranot Hishtalmut Le Morim Ve Gananot Havera Menahelet Tel Aviv, Israel $2.44B AUM 24.95% 1-Year Est. Return
YDMI
Y.D. More Investments Ramat Gan, Israel $3.21B AUM 117.29% 1-Year Est. Return

Victrix Investment Advisors's TEVA Position: Q2 2026 in Review

Victrix Investment Advisors increased its Teva Pharmaceuticals (TEVA) stake by 9.5% in Q2 2026, buying an estimated $22.7K and bringing the position to 7,850 shares worth $266K. The position accounts for 0.11% of the portfolio, ranked #68.

Victrix Investment Advisors first reported a position in TEVA in Q1 2026 and has held it in 2 quarters since. 332 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Victrix Investment Advisors held 7,850 shares of Teva Pharmaceuticals worth $266K as of Q2 2026.
  • Victrix Investment Advisors bought 681 Teva Pharmaceuticals shares in Q2 2026, an estimated $22.7K.
  • Teva Pharmaceuticals made up 0.11% of Victrix Investment Advisors's portfolio in Q2 2026, its #68 holding.
  • Victrix Investment Advisors first reported a position in Teva Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 332 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Victrix Investment Advisors's 13F filing for Q2 2026, filed 8 Jul 2026.